Literature DB >> 10758303

Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy.

A Trotti1, R Byhardt, J Stetz, C Gwede, B Corn, K Fu, L Gunderson, B McCormick, M Morrisintegral, T Rich, W Shipley, W Curran.   

Abstract

In 1997, the National Cancer Institute (NCI) led an effort to revise and expand the Common Toxicity Criteria (CTC) with the goal of integrating systemic agent, radiation, and surgical criteria into a comprehensive and standardized system. Representatives from the Radiation Therapy Oncology Group (RTOG) participated in this process in an effort to improve acute radiation related criteria and to achieve better clarity and consistency among modalities. CTC v. 2.0 replaces the previous NCI CTC and the RTOG Acute Radiation Morbidity Scoring Criteria and includes more than 260 individual adverse events with more than 100 of these applicable to acute radiation effects. One of the advantages of the revised criteria for radiation oncology is the opportunity to grade acute radiation effects not adequately captured under the previous RTOG system. A pilot study conducted by the RTOG indicated the new criteria are indeed more comprehensive and were preferred by research associates. CTC v. 2.0 represents an improvement in the evaluation and grading of acute toxicity for all modalities.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10758303     DOI: 10.1016/s0360-3016(99)00559-3

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  186 in total

1.  Prognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib era.

Authors:  Haiyan He; Yang Shen; Yongmei Zhu; Saijuan Chen
Journal:  Front Med       Date:  2012-06-03       Impact factor: 4.592

2.  Simultaneous neoadjuvant radiochemotherapy with capecitabine and oxaliplatin for locally advanced rectal cancer. Treatment outcome outside clinical trials.

Authors:  J Winkler; L Zipp; J Knoblich; F Zimmermann
Journal:  Strahlenther Onkol       Date:  2012-03-10       Impact factor: 3.621

3.  Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1-2 trial.

Authors:  Xin Shelley Wang; Laurence D Rhines; Almon S Shiu; James N Yang; Ugur Selek; Ibrahima Gning; Ping Liu; Pamela K Allen; Syed S Azeem; Paul D Brown; Hadley J Sharp; David C Weksberg; Charles S Cleeland; Eric L Chang
Journal:  Lancet Oncol       Date:  2012-01-27       Impact factor: 41.316

4.  Radiation recall dermatitis with azithromycin.

Authors:  O Vujovic
Journal:  Curr Oncol       Date:  2010-08       Impact factor: 3.677

5.  Unintended consequences of evolution of the Common Terminology Criteria for Adverse Events.

Authors:  Tamara P Miller; Brian T Fisher; Kelly D Getz; Leah Sack; Hanieh Razzaghi; Alix E Seif; Rochelle Bagatell; Peter C Adamson; Richard Aplenc
Journal:  Pediatr Blood Cancer       Date:  2019-04-09       Impact factor: 3.167

6.  Photocontrolled miR-148b nanoparticles cause apoptosis, inflammation and regression of Ras induced epidermal squamous cell carcinomas in mice.

Authors:  Yiming Liu; Jacob T Bailey; Mohammad Abu-Laban; Shue Li; Cong Chen; Adam B Glick; Daniel J Hayes
Journal:  Biomaterials       Date:  2020-06-22       Impact factor: 12.479

7.  A phase I study of oral ZD 1839 given daily in patients with solid tumors: IND.122, a study of the Investigational New Drug Program of the National Cancer Institute of Canada Clinical Trials Group.

Authors:  G Goss; H Hirte; W H Miller; I A J Lorimer; D Stewart; G Batist; D A E Parolin; P Hanna; S Stafford; J Friedmann; W Walsh; S Mathews; L Douglas; L K Seymour
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

8.  A phase II trial of ZD1839 (Iressa) 750 mg per day, an oral epidermal growth factor receptor-tyrosine kinase inhibitor, in patients with metastatic colorectal cancer.

Authors:  Mary J Mackenzie; Holger W Hirte; Goss Glenwood; Maroun Jean; Rakesh Goel; Pierre P Major; Wilson H Miller; Lawrence Panasci; Ian A J Lorimer; Gerald Batist; Sarah Matthews; Lynn Douglas; Lesley Seymour
Journal:  Invest New Drugs       Date:  2005-03       Impact factor: 3.850

9.  Donepezil and vitamin E for preventing cognitive dysfunction in small cell lung cancer patients: preliminary results and suggestions for future study designs.

Authors:  Aminah Jatoi; Stephen P Kahanic; Stephen Frytak; Paul Schaefer; Robert L Foote; Jeff Sloan; Ronald C Petersen
Journal:  Support Care Cancer       Date:  2004-10-09       Impact factor: 3.603

10.  High-grade acute organ toxicity during preoperative radiochemotherapy as positive predictor for complete histopathologic tumor regression in multimodal treatment of locally advanced rectal cancer.

Authors:  Hendrik Andreas Wolff; Jochen Gaedcke; Klaus Jung; Robert Michael Hermann; Hilka Rothe; Markus Schirmer; Torsten Liersch; Markus Karl Alfred Herrmann; Steffen Hennies; Margret Rave-Fränk; Clemens Friedrich Hess; Hans Christiansen
Journal:  Strahlenther Onkol       Date:  2009-12-28       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.